Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Qaseem A, Obley AJ, Yost J, Abraham GM, Andrews RA, Jokela JA, Miller MC, Humphrey LL, Haeme R, Krain A, Poonacha T, Saini SD, Wilt TJ, Carroll K, Etxeandia-Ikobaltzeta I, Harrod CS, Shamliyan T, Vigna C. Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3). Ann Intern Med. 2026 Apr; 179(4):559-563.
-
Yogaratnam D, Mukherjee SM, Getchell K, Dima L. Omalizumab: First Approved Anti-IgE Therapy for Multiple Food Allergies. Am J Ther. 2026 Jan-Feb 01; 33(1):e39-e45.
-
Marzo-Ortega H, Navarro-Compan V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 2025 11 28; 11(4).
-
Xu C, Liang XY, Huang XQ, Jin F, Yang KY, Hu GY, Zhu XD, Wang Y, Huang Y, Zhang N, Hu DS, Guo L, Zou GR, Chen XZ, Xiao SW, Li JG, Shen LF, Li YY, Huang J, Long GX, Li L, Huang L, She LJ, Wu Y, Zeng WH, Qiang MY, Liu WX, Su Y, Tang LL, Xie FY, Han F, Lu LX, Xiang YQ, Mao YP, Li WF, Liu X, Yang Q, Zhou GQ, Guo R, Ouyang PY, Wang XH, Chen L, Liu LT, Lin L, Li JB, Lin AH, Zhao HY, Hong SB, Jie YS, Huang HL, Tang XH, Zeng YC, Yun JP, Zang SB, Du ZM, Ye ZL, Liu LZ, Tian L, Li HJ, Peng YL, Liu N, Li YQ, Liang YL, Wei HM, Chen YP, Zhang Y, Du XJ, Lv JW, Sun Y, Ma J. Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial. JAMA. 2025 Sep 16; 334(11):973-983.
-
Meara EM, Curran DL, Wiss K, Plumptre I. Eosinophilic Plastic Bronchitis in a Child With Palmoplantar Psoriasis Treated With Ustekinumab. Pediatr Dermatol. 2026 Jan-Feb; 43(1):163-165.
-
Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi I, Sato T, Shaheen M, Zhao L, Kelley H, Liu H, Kumar S, Bobilev D, Krieg AM, Wooldridge JE, Kirkwood JM. Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025 Aug 01; 131(15):e70022.
-
Meinel TR, B?cke P, D'Anna L, Merlino G, Aguiar de Sousa D, Poli S, Purrucker JC, Strambo D, Romoli M, De Marchis GM, Pfeilschifter W, Zedde M, Marto JP, Candelaresi P, Lemmens R, Scoppettuolo P, Woock M, Kermer P, Kristoffersen ES, Ghannam M, Frol S, Nolte CH, Yakushiji Y, Touz? E, Uphaus T, Mannino M, Ntaios G, Padjen V, Henninger N, Zipser-Mohammadzada F, Mariano ME, Guerreiro C, Burini A, Ceccarelli L, Valente M, Gomez-Exposito A, Kleeberg A, Thevoz G, Michel P, Stufano G, Vlachos D, Herrmann M, Rodrigues B, Spina E, Andreone V, Allardt A, Alshaer QN, Riegler C, Kunieda T, Boulanger M, Hahn M, Papadimitriou D, Muppa J, Maes L, Ranta A, Tyson A, Barber PA, Davis AJ, Wu TY, Kaesmacher J, Fischer U, Seiffge DJ. Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use. Stroke. 2025 Oct; 56(10):2836-2845.
-
Li X, Singh S, DeVries A, Gurwitz JH. Lecanemab Therapy Use Patterns for Alzheimer's Disease Among Early Initiators in a Large National Health Plan. J Am Geriatr Soc. 2025 Oct; 73(10):3203-3207.
-
Randall L, Xiang Y, Matsumoto T, Giannarelli D, Milla DP, Lopez KA, Acevedo A, Vizkeleti J, Salani R, Nogueira-Rodrigues A, Mejia FC, Korach J, Akilli H, Lee JY, Saevets VV, Samouelian V, Sehouli J, Tharavichikul E, Sukhin V, Colombo N, Chang CL, Cueva JF, Lalondrelle S, Petru E, Szamreta E, Nguyen AM, Yamada K, Li K, Pignata S, Lorusso D. Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer. Gynecol Oncol. 2025 Aug; 199:88-95.
-
Ostermann M, Corteville DC, Doi K, Koyner JL, Lamy A, Li G, Solinsky CM, Winterberg PD, Smith WT, Mehta RL, Murray PT, Shaw AD, Zarbock A, Engelman DT. A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials. 2025 May 30; 26(1):181.